% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Bhardwaj:153230,
author = {M. Bhardwaj$^*$ and K. Weigl$^*$ and K. Tikk$^*$ and T.
Holland-Letz$^*$ and P. Schrotz-King$^*$ and C. H. Borchers
and H. Brenner$^*$},
title = {{M}ultiplex quantitation of 270 plasma protein markers to
identify a signature for early detection of colorectal
cancer.},
journal = {European journal of cancer},
volume = {127},
issn = {0959-8049},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2020-00263},
pages = {30 - 40},
year = {2020},
note = {#EA:C120#LA:C120#},
abstract = {Blood-based protein biomarker signatures might be an
alternative or supplement to existing methods for early
detection of colorectal cancer (CRC) for population-based
screening. The objective of this study was to derive a
protein biomarker signature for early detection of CRC and
its precursor advanced adenoma (AA). In a two-stage design,
270 protein markers were measured by liquid
chromatography/multiple reaction monitoring/mass
spectrometry in plasma samples of discovery and validation
sets. In the discovery set consisting of 100 newly diagnosed
CRC cases and 100 age- and sex-matched controls free of
neoplasm at screening colonoscopy, the algorithms predicting
the presence of early- or late-stage CRC were derived by
Lasso regression and .632 + bootstrap. The prediction
algorithms were then externally validated in an independent
validation set consisting of participants of screening
colonoscopy including 56 participants with CRC, 99 with AA
and 99 controls without any colorectal neoplasms. Three
different signatures for all-, early- and late-stage CRC
consisting of five-, three- and eight-protein markers were
obtained in the discovery set with areas under the curves
(AUCs) after .632 + bootstrap adjustment of 0.85, 0.83 and
0.96, respectively. External validation in the
representative screening population yielded AUCs of 0.79
$(95\%$ CI, 0.70-0.86), 0.79 $(95\%$ CI, 0.66-0.89) and 0.80
$(95\%$ CI, 0.70-0.89) for all-, early- and late-stage CRCs,
respectively. The three-marker early-stage algorithm yielded
an AUC of 0.65 $(95\%$ CI, 0.56-0.73) for detection of AA in
the validation set. Although not yet competitive with
available stool-based tests for CRC early detection, the
identified proteins may contribute to the development of
powerful blood-based tests for early detection of CRC and
its precursors AAs.},
cin = {C120 / C070 / HD01},
ddc = {610},
cid = {I:(DE-He78)C120-20160331 / I:(DE-He78)C070-20160331 /
I:(DE-He78)HD01-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31972396},
doi = {10.1016/j.ejca.2019.11.021},
url = {https://inrepo02.dkfz.de/record/153230},
}